报价延迟最少15分钟:2025/09/04 02:29 EDT
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
9.46 
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-2.60/-3.89
|
|
企业价值
716.74M
|
| 资产负债 |
|
每股账面净值
5.85
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
54.55M
|
|
每股收益
0.90
|
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
报价延迟最少15分钟：2025/09/04 02:29 EDT
同行比较之报价最少15分钟延迟
|
业务概览
|
|||
| Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies. |
